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Abstract
We conducted a prospective study to assess the risk factors, molecular epidemiology and outcome of bloodstream
infection (BSI) due to Enterococcus faecium in hospitalized cancer patients. Between 2006 and 2012, a significant
increase in vancomycin-susceptible E. faecium BSI was observed among cancer patients. Comparison of 54
episodes of BSI due to E. faecium with 38 episodes of BSI due to E. faecalis showed that previous use of
carbapenems was the only independent risk factor for E. faecium acquisition (OR 10.24; 95% CI, 1.35-77.66). All E.
faecium isolates were susceptible to glycopeptides, whereas 97% showed high-level resistance to ampicillin and
ciprofloxacin. All 30 isolates available for genotyping belonged to the hospital-associated E. faecium lineages 17, 18
and 78. After 2009, most of the isolates belonged to ST117 (lineage 78). Patients with E. faecium BSI were more
likely to receive inadequate initial empirical antibiotic therapy than patients with E. faecalis BSI, and time to adequate
empirical antibiotic therapy was also longer in the former group. No significant differences were found between the
two groups regarding early and overall case-fatality rates. Independent risk factors for overall case-fatality were
current corticosteroids (OR 4.18; 95% CI, 1.34-13.01) and intensive care unit admission (OR 9.97; 95% CI,
1.96-50.63). The emergence of E. faecium among cancer patients is a concern since there are limited treatment
options and it may presage the emergence of vancomycin-resistant enterococci. A rationale approach that combines
infection control with antimicrobial stewardship.
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Introduction
Enterococci are part of the normal human microbial flora.
Historically, the majority of invasive enterococcal infections
were caused by Enterococcus faecalis, followed by
Enterococcus faecium [1]. In recent decades, however, the
epidemiology of invasive enterococcal infections appears to be
changing worldwide, and a number of trends have been
recognized, notably, the global emergence of enterococci as
important nosocomial pathogens and the emergence of
resistance to commonly used antimicrobial agents, including
penicillins, aminoglycosides and glycopeptides [1].
An increase in the number of E. faecium strains in hospitals
in different countries has been documented during the last
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decade [2-4]. These isolates had in common not only the
antibiotic resistance traits (to ampicillin, quinolones and to
glycopeptides in some cases) but also several virulence factors
that might have contributed to the success of E. faecium as a
leading nosocomial pathogen [4,5]. Although these strains
were initially classified within a single clonal complex 17, it
appears that the genetic diversity of this CC allows the
classification of all isolates in three main lineages (17, 18, and
78), which is a more accurate representation of the recent
evolution of these isolates[6].
Management of severe infections due to resistant
enterococcal strains, especially E. faecium, has therefore
become a therapeutical challenge. However, most of the
reported experiences regarding enterococcal infections
concern the general, non-immunocompromised population, and
they mainly involve vancomycin-resistant strains [7-12].
Additionally, the majority of the studies published to date have
been carried out in the United States, where the
epidemiological situation is very different from that occurring in
Europe [1,13]. Furthermore, information regarding bloodstream
infection (BSI) due to E. faecium in immunosuppressed
patients with cancer is particularly scarce [10,11,14,15]. Given
the above, the aim of the present study was to describe the
incidence and risk factors for vancomycin-susceptible E.
faecium BSI in a large prospective cohort of cancer patients.
We also aimed to ascertain the clinical features, antimicrobial
susceptibility, genotypes and outcome of BSI due to E. faecium
in this population.
Materials and Methods
Setting, patients and study design
We conducted a prospective observational study in a 200-
bed cancer referral centre for adults in Barcelona, Spain. From
1 January 2006 to 30 September 2012 all hospitalized cancer
patients and haematopoietic stem cell transplant recipients with
at least one episode of BSI were included in the study.
Information on baseline characteristics, clinical features,
empirical antibiotic therapy and outcome was carefully
recorded in a specific database.
All episodes of BSI due to vancomycin-susceptible E.
faecium were compared with those caused by vancomycin-
susceptible Enterococcus faecalis in order to identify the risk
factors for ampicillin resistance acquisition and to assess
differences in clinical features and outcome. We also compared
patients who died with those who survived in order to identify
risk factors for mortality.
All BSI episodes at our hospital are reported and followed up
by an infectious disease physician. Changes in antimicrobial
treatment and general management were advised when
necessary.
Ethics statement
This observational study was approved by the Institutional
Review Board Comité Ético de Investigación Clínica del
Hospital Universitari de Bellvitge (Ethics Committee of Clinical
Research-Hospital Universitari de Bellvitge), with the following
reference number PR 232/10. To protect personal privacy,
identifying information of each patient in the electronic
database was encrypted. Informed consent was waived by the
Clinical Research Ethics Committee because no intervention
was involved and no patient identifying information was
included.
Definitions
Neutropenia was defined as an absolute neutrophil count
<500/mm3. Current corticosteroid therapy was recorded when a
patient was receiving corticosteroids at the time of the BSI
episode or in the previous month. Prior antibiotic therapy was
defined as the receipt of any systemic antibiotic for >48 hours
during the previous month. BSI was considered to be from an
endogenous source in those patients with neutropenia in whom
no other BSI sites were identified. In those patients without
neutropenia, an unknown source was considered if an evident
origin of the infection was not identified [16]. Shock was
defined as a systolic pressure <90 mmHg that was
unresponsive to fluid treatment or which required vasoactive
drug therapy. Empirical antibiotic therapy was considered
inadequate if the treatment regimen did not include at least one
antibiotic active in vitro against the infecting microorganism.
Early case-fatality rate was defined as death within 48 hours of
the BSI episode. Overall case-fatality rate was defined as
death by any cause within the first 30 days of the onset of BSI.
Microbiological studies
Blood cultures were performed by standard methods. Two
sets of two blood samples were drawn from patients with
suspected bloodstream infection. Blood samples were
processed by the BACTEC 9240 system (Becton Dickinson
Microbiology Systems) with an incubation period of five days.
Positive blood samples were sub-cultured onto chocolate agar.
Identification and antibiotic susceptibility were performed using
commercially available plates (MicroScan, Siemens), following
the manufacturer’s instructions. The antimicrobial susceptibility
of isolates was interpreted according to current Clinical
Laboratory Standard Institute criteria [17].
Thirty E. faecium strains isolated between 2006 and 2012
from single bacteraemic patients were available for genotyping.
Pulsed field gel electrophoresis (PFGE) was performed in all
strains after SmaI restriction of chromosomal DNA, as
previously described [18]. PFGE patterns were interpreted both
by visual inspection, using the criteria of van Belkum et al. and
by analysis with the FINGERPRINTING TM II software, version
3.0 (BioRad Laboratories, Inc., Madrid, Spain) [19].
Dendrograms were constructed using Dice coefficients, with
optimization and band position tolerance being set to 0.5% and
1% respectively. A similarity coefficient of 80% was selected to
define the patterns.
Multilocus sequence typing (MLST) was conducted on 17
representative strains of each SmaI-PFGE type, as described
by Homan et al. [20]. Sequence types (STs) were assigned
according to the E. faecium MLST database (http://
efaecium.mlst.net).
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Statistical analysis
Continuous variables were compared by means of the Mann-
Whitney U test and t-test. Qualitative variables were compared
using the chi-square test, and odds ratios and 95% confidence
intervals were calculated. Multivariate conditional logistic
regression analysis of factors potentially associated with E.
faecium acquisition and mortality included all statistically
significant variables in the univariate analysis, sex and age,
and all clinically important variables regardless of whether they
were statistically significant or not [21]. This analysis was
performed with the stepwise logistic regression model of the
SPSS software package (SPSS v. 17).
Results
During the study period 1287 consecutive episodes of BSI
were recorded. Of the 550 (42.5%) episodes caused by Gram-
positive bacteria, 105 were due to enterococci (19%). Thirteen
episodes of enterococcal BSI were not included in the study
because they were caused by species other than E. faecium or
E. faecalis (E. gallinarum 6, E. casseliflavus 2, E. avium 2, E.
hirae 1, E. durans and E. raffinosus 1). Thus, 54 episodes of
BSI caused by E. faecium and 38 by E. faecalis were finally
included in the study. Four patients with two episodes of
enterococcal BSI were included since they were considered to
present different episodes, separated by at least four weeks.
The incidence of E. faecium BSI increased significantly over
time (22 episodes/126610 admissions from 2006 to 2009 vs 32
episodes/80586 admissions from 2010 to September 2012;
p=0.002). By contrast, the incidence of E. faecalis BSI
remained stable over time (p=0.215).
Table 1 shows the baseline and clinical characteristics of
patients with enterococcal BSI compared by groups. Patients
with BSI due to E. faecium were more likely to have received
previous antibiotics (mainly carbapenems), previous antifungal
prophylaxis and previous blood transfusion. Likewise, they had
more prolonged neutropenia than did patients with E. faecalis
BSI, and were more likely to have a concomitant infection. In
addition, there was a trend in the former group of patients
towards haematological malignancy as the most frequent
underlying disease, and for there to be a venous catheter in
place. The most frequent origin of BSI was an endogenous
source in 38% of cases (41% in the E. faecium group vs 34%
in the E. faecalis group), followed by catheter infection in 15%
of cases (15% vs 16%, respectively) and cholangitis in 13%
(15% vs 10.5%, respectively). BSI originating in the urinary
tract tended to be more frequent in the group of E. faecalis,
whereas neutropenic enterocolitis tended to be more frequent
in the E. faecium group. After applying a logistic regression
model the only variable found to be an independent risk factors
for E. faecium acquisition was previous use of carbapenems
(OR 10.24; 95% CI, 1.35-77.66).
Microbiological studies
All E. faecium isolates were vancomycin and teicoplanin
susceptible. Only two strains (2.9%) of the 54 isolates were
ampicillin susceptible with MICs ≤1 µg/mL. During the study
period 97.1% of strains showed high-level resistance to
Table 1. Baseline and clinical characteristics of all episodes
of enterococal bacteraemia and risk factors for E. faecium
acquisition.
 E. faecalis E. faecium p Adjusted OR p
Characteristic n=38 (%) n=54 (%)  (95%CI)  
Male sex 27 (71) 32 (59) 0.27 1.70(0.29-9.81) 0.55
Age (yrs, median,
range) 61 (26-78) 59 (21-83) 0.15
0.99
(0.94-1.05) 0.98
Underlying disease   0.074   
 Solid tumour 15 (39.5) 12 (22)    
 Haematological
malignancy 23 (60.5) 42 (78)    
Haematopoietic stem
cell transplant (HSCT) 2 (5) 7 (13) 0.29   
Type of HSCT      
 Autologous 1 1 0.41   
 Allogeneic 0 4 -   
  Dual 1 2 -   
Graft-versus-host
disease 0 2 (4) 0.50   
Comorbidities 16 (42) 21 (39) 0.83   
 Diabetes mellitus 6 (16) 8 (15) 1.00   
 Chronic obstructive
pulmonary disease 2 (5) 1 (2) 0.56   
 Chronic heart
disease 7 (18) 7 (13) 0.56   
 Chronic renal failure 1 (3) 3 (6) 0.64   
 Chronic liver disease 2 (5) 1 (2) 0.56   
Neutrophil count < 500 19 (50) 35 (65) 0.19   
Previous days with
neutropenia (< 500)
(median, range)
8 (0-35) 11 (1-60) 0.028 0.99(0.92-1.07) 0.95
MASCC ≥ 21 9 (56) 17 (55) 1.00   
Chemotherapy (within
1 month) 23 (60.5) 41 (76) 0.16   
Radiotherapy (within 1
month) 1 (3) 4 (7) 0.40   
Corticosteroid therapy
(within 1 month) 18 (47) 19 (35) 0.28   
Antifungal prophylaxis 12 (32) 32 (59) 0.011 1.31(0.20-8.35) 0.77
Previous antibiotic
therapy (within 1
month)
24 (63) 52 (96) <.001 10.24(1.35-77.66) 0.024
 Carbapenems  3 (12,5) 27 (52) 0.001   
 β-lactam + β-lactam
inhibitor 5 (21) 18 (35) 0.28   
 Cephalosporin 14 (58) 29 (56) 1.00   
 Quinolone 2 (8) 12 (23) 0.20   
 Aminoglycoside 1 (4) 1 (2) 0.53   
 Glycopeptide 5 (21) 10 (19) 1.0   
Severe mucositis
(grade III-IV) 3 (8) 10 (18.5) 0.22   
Urinary catheter 10 (26) 11 (21) 0.61   
Venous catheter 28 (74) 48 (89) 0.058   
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ampicillin, and the rates of high-level resistance to streptomycin
and gentamycin were 74.6% and 32.8%, respectively.
Quinolone resistance accounted for 88.8% of the isolates, with
MICs ≥4 µg/mL.
Among 30 ampicillin-resistant E. faecium strains available for
genotyping, 13 PFGE patterns were obtained corresponding to
7 STs (Figure 1). ST117 was dominant, accounting for 16
isolates (53.3%) belonging to PFGE type D (n=10; 62.5%) and
PFGE type A (n=6; 37.5%). Five isolates (16.7%) belonged to
ST17 of PFGE type B (n=4) and H (n=1), three isolates (10%)
belonged to ST 78, two (6.7%), to ST18, two (6.7%) to ST203
and one to ST192. A single isolate belonged to a new ST844
(Table S1). Considering the new classification recently
proposed by Willems and co-workers, 5 isolates belonged to
lineage 17 (ST17), two isolates belonged to lineage 18 (ST18)
and 23 isolates belonged to lineage 78 (ST78, ST117, ST192,
ST203 and ST844) [6]. From 2006 to 2009, one isolate out of
eight available for genotyping belonged to ST117 (year 2009).
In contrast, from 2010 to 2012, 15 out of 22 isolates belonged
to ST117, with PFGE patterns D (n=10) and A (n=5). The allelic
profiles for all different STs are detailed in Table S1.
Table 1 (continued).
 E. faecalis E. faecium p Adjusted OR p
 Central venous
catheter 15 (39.5) 28 (52) 0.29   
Previous hospital
admission (within 3
months)
16 (42) 26 (49) 0.53   
Previous ICU
admission (within 3
months)
5 (13) 7 (13) 1.00   
Previous episode of
bacteremia 10 (26) 20 (38) 0.27   
Previous blood
transfusion (within 5
days)
10 (28) 26 (51) 0.046 0.57 (0.12-2.6) 0.48
Concomitant infection 4 (11) 15 (29) 0.041 8.4(0.80-88.33) 0.076
Axillary temperature ≥
38 C 35 (92) 46 (85) 0.51   
Polymicrobial
bacteraemia 9 (24) 11 (20) 0.79   
Persistent bacteraemia 4 (11) 7 (15) 0.75   
Shock at presentation 4 (10.5) 2 (4) 0.22   
Source of bacteraemia      
 Endogenous source 13 (34) 22 (41) 0.66   
 Gastrointestinal tract 3 (8) 3 (6) 0.68   
 Neutropenic
enterocolitis 1 (3) 8 (15) 0.076   
 Cholangitis 4 (10.5) 8 (15) 0.75   
 Urinary tract 5 (13) 1 (2) 0.078   
 Catheter-related 6 (16) 8 (15) 1.00   
 Unknown 5 (13) 3 (6) 0.26   
doi: 10.1371/journal.pone.0074734.t001
Antibiotic treatment and patient outcomes are detailed in
Table 2. The large majority of patients received empirical
antibiotic therapy (91%). The most frequently antibiotic used
was a glycopeptide (42% of cases), followed by third- and
fourth-generation cephalosporins (29%), β-lactam plus β-
lactam inhibitors (26%) and carbapenems (25%). More patients
with E. faecalis BSI received a combination of a β-lactam plus
β-lactam inhibitor empirically, whereas more patients in the E.
faecium group were given a glycopeptide. Patients with E.
faecium BSI were more likely to have received inadequate
initial empirical antibiotic therapy than were patients with E.
faecalis BSI, and time to adequate empirical antibiotic therapy
was also longer in the former group. No significant differences
were found between the two groups regarding other outcomes
such as early and overall mortality rates.
Risk factors associated with overall case-fatality in the cohort
of patients with enterococcal BSI are shown in Table 3. The
use of current corticosteroids, shock at presentation, intensive
care unit (ICU) admission, mechanical ventilation and unknown
source of BSI were the variables most frequently found in the
group of patients who died. However, after applying a logistic
regression model the only variables found to be independent
risk factors for overall case-fatality were the current use of
corticosteroids (OR 4.18; 95% CI, 1.34-13.01) and ICU
admission (OR 9.97; 95% CI, 1.96-50.63). BSI due to E.
faecium was not identified as a risk factor for overall mortality.
Table 2. Antibiotic therapy and outcome of patients with
enterococal bacteraemia compared by groups.
 E. faecalis E. faecium p
 n=38 (%) n=54 (%)  
Empirical antibiotic therapy 35 (92) 49 (91) 1.00
Inadequate empirical antibiotic therapy 9 (24) 24 (44) 0.041
 β-lactam + β-lactam inhibitor 13 (37) 9 (18) 0.054
 Cephalosporin 11 (31) 13 (26.5) 0.63
 Carbapenem 8 (23) 13 (26.5) 0.80
 Glycopeptide 10 (29) 25 (51) 0.046
 Quinolone 1 (3) 2 (4) 1.00
 Aminoglycoside 5 (14) 5 (10) 0.73
 Combination therapy 8 (23) 6 (12) 0.24
Days to adequate empirical antibiotic
therapy (median, range) 0 (0-6) 1 (0-4) 0.036
Intensive care unit admission 5 (13) 7 (13) 1.00
Mechanical ventilation 2 (6) 4 (8) 1.00
Overall case-fatality rate (30 days) 10 (26) 16 (30) 0.72
Early case-fatality rate (48 hours) 1 (3) 3 (6) 0.64
doi: 10.1371/journal.pone.0074734.t002
Enterococcus faecium Bacteremia in Cancer Patients
PLOS ONE | www.plosone.org 4 September 2013 | Volume 8 | Issue 9 | e74734
Discussion
We observed a dramatic increase in the incidence of
ampicillin-resistant, vancomycin-susceptible E. faecium BSI in
patients with cancer over the study period. Historically, E.
faecalis was the responsible for the large majority of all clinical
enterococcal infections, with E. faecium being less frequently
isolated. However, in the late 1990s the ratio of E. faecalis to E.
faecium infections in the United States shifted in favour of E.
faecium, while in Europe the first reports of increased numbers
of infections due to E. faecium were published in the mid-1990s
[1,9,13]. Despite this, information regarding BSI caused by
vancomycin-susceptible E. faecium in immunosuppressed
cancer patients is scarce in the literature, and all the articles
published to date are retrospective studies [11,14,15,22]. Thus,
our study is the first prospective analysis of a cohort of cancer
patients with vancomycin-susceptible E. faecium BSI to be
conducted at a time when enterococcal infections are gaining
importance worldwide, both in terms of dissemination and
antimicrobial resistance. It is also the first study to describe
how vancomycin-susceptible E. faecium outnumbers E.
faecalis in this high-risk population of patients with BSI in our
geographical area.
Although several studies have focused on risk factors for
vancomycin-resistant enterococcal infection or colonization
[23,24], little is known about risk factors for BSI due to
vancomycin-susceptible E. faecium. In our study we identified
previous use of carbapenems as the only independent risk
Figure 1.  Cluster analysis of Pulsed-field Gel Electrophoresis (PFGE) SmaI macrorestriction fragments of the 30
Enterococcus faecium strains followed by multilocus sequence typing (MLST) data.  MLST was inferred in those strains that
were marked with an asterisk. For dendrogram construction, optimization and band position tolerance were set at 0.5% and 1.0%
respectively. The cut-off value to define the PFGE patterns was set at 80% similarity.
doi: 10.1371/journal.pone.0074734.g001
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factor associated with E. faecium BSI. Since the early research
of Boyce et al., which related ampicillin-resistant enterococci to
the use of imipenem, several authors have demonstrated the
association of ampicillin-resistant enterococci with β-lactams
[9-11,16,25]. Antibiotics may facilitate colonization and infection
by depleting the gastrointestinal tract of its normal anaerobic
flora and by selecting enterococci due to limited bactericidal
activity against these organisms. The use of broad spectrum β-
lactams (including carbapenems) in patients with cancer and
frequently-associated febrile neutropenia is very common in
clinical practice. Furthermore, the emergence of multidrug-
resistant organisms (especially extended-spectrum β-
lactamase-producing Enterobacteriaceae) among cancer
patients in our centre often forces us to use carbapenems as
the treatment of choice [26]. A judicious use of antibiotics is
therefore needed in order to avoid the development and
dissemination of bacterial resistance.
Our study shows that all the enterococci isolates remained
susceptible to glycopeptides. Although vancomycin resistance
has become an emerging health problem worldwide, it is less
important in Europe than in the United States, and as yet it
does not seem to be a problem in our geographical area [1,13].
However, the emergence of E. faecium is of potential concern
as it is more commonly associated with vancomycin resistance
than are the other enterococci [27]. The large majority of E.
faecium isolates showed a high level of resistance to ampicillin,
and only two strains were ampicillin susceptible. Notably, the
two patients carrying the two susceptible strains had not
received carbapenems previously.
Table 3. Risk factors for overall mortality (30 days) in the
cohort of patients with enterococcal bacteraemia.
 E. faecalis E. faecium p Adjusted OR p
Characteristic n=38 (%) n=54 (%)  (95%CI)  
Male sex 43 (65) 16 (61.5) 0.81 1.23 (0.38-3.89) 0.72
Age (yrs, median,
range) 61 (26-78) 59 (21-83) 0.15 0.99 (0.95-1.03 0.65
Underlying
haematological
disease
49 (74) 16 (61.5) 0.30   
Neutropenia (<500) 40 (61) 14 (54) 0.64   
Corticosteroids 20 (30) 17 (65) 0.004 4.18(1.34-13.01) 0.013
Shock at presentation 1 (1.5) 5 (19) 0.006 3.43(0.27-43.70) 0.34
Inadequate empirical
antibiotic therapy 26 (39) 7 (27) 0.33   
Intensive care unit
admission 3 (4.5) 9 (35) <.001
9.97
(1.96-50.63) 0.006
Mechanical
ventilation 1 (2) 5 (22) 0.005   
Unknown source of
bacteraemia 3 (4.5) 5 (19) 0.038
3.99
(0.68-23.40) 0.12
E. faecium
bacteraemia 38 (58) 16 (61.5) 0.81   
doi: 10.1371/journal.pone.0074734.t003
PFGE and MLST analysis of 30 available E. faecium isolates
showed that all isolates belonged to the three major recently
described hospital-associated E. faecium lineages (17, 18 and
78) [6]. Of note, the ST117 (lineage 78) was especially frequent
in the last three years, which may explain, at least partially, the
emergence of E. faecium in our centre. This finding is in line
with recent molecular epidemiological studies that have
identified these three lineages (formerly CC17) as being
responsible for the worldwide emergence of ampicillin-resistant
E. faecium. These three lineages have adapted extremely well
to the hospital environment, including the acquisition of
ampicillin resistance and the esp virulence gene, which is
associated with biofilm formation. Therefore, these lineages
have become the leading cause of hospital-acquired E.
faecium infections and outbreaks [2-4,28]. The partial
replacement of ampicillin-susceptible E. faecalis by hospital-
associated lineages of ampicillin-resistant E. faecium is
worrying, since it may set the stage for the emergence of
vancomycin-resistant E. faecium.
There is controversy in the literature regarding the
association between E. faecium infection and mortality. Some
authors have reported increased mortality in those patients with
BSI due to ampicillin-resistant E. faecium [7,10,16]. However, it
is still unclear if the increase in mortality actually depends on
infection or, rather, whether infection behaves as a marker of
the severity of underlying diseases [29]. In our study, and in
line with some previous reports, we found no association
between E. faecium BSI and increased mortality [8,9,14,28].
Interestingly, some in vitro studies have suggested that
enterococcal virulence determinants are more frequently found
in E. faecalis isolates than in E. faecium isolates [30]. On the
other hand, some studies have reported that E. faecium is
more often resistant to phagocytosis than is E. faecalis [31].
Whether there is a clinically relevant difference in virulence
between vancomycin-resistant enterococci and vancomycin-
susceptible enterococci, or between different enterococcal
species is unknown.
The only variables found to be independent risk factors for
mortality in our study were ICU admission and current
corticosteroid therapy. ICU admission is associated with severe
sepsis and shock, which are known to be risk factors for
mortality in patients with BSI [7]. Patients receiving
corticosteroid therapy mainly corresponded to debilitated
patients with severe uncontrolled underlying disease, who are
known to be a risk group for poor outcome.
Patients with E. faecium BSI in our study were more likely to
receive inadequate empirical antibiotic therapy. Inadequate
empirical antibiotic therapy has previously been reported to be
associated with mortality, especially in patients with Gram-
negative BSI and in those with vancomycin-resistant
enterococcal infections [32]. However, this association was not
observed in our study. A retrospective study by DiazGranados
et al. identified vancomycin-resistance as a risk factor for
mortality in neutropenic cancer patients. However, it was not
associated with inadequate empirical antibiotic therapy, but
rather was attributed to prolonged duration of BSI [15]. Factors
influencing mortality among cancer patients are often difficult to
asses.
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The emergence of E. faecium in immunosuppressed patients
with cancer is a concern, since there are limited therapeutic
options for these organisms. Although new antimicrobials, such
as linezolid, daptomycin and quinupristin/dalfopristin, have
recently been developed to treat serious enterococcal
infections, resistance to these agents has already emerged
[33-35].
This study has a number of strengths. It describes the
incidence of E. faecium BSI in a large cohort of BSI episodes
prospectively collected in a specific immunosuppressed high-
risk population. Additionally, it provides information regarding
the E. faecium clonal complexes identified during the study
period. However, it also has certain limitations. The small
number of patients in the two groups may have prevented us
from identifying significant differences between them. Also, as
this was a single-centre study the results may have been
influenced by local epidemiological variables, thereby limiting
their applicability to other settings.
In conclusion, we found a significant increase in vancomycin-
susceptible E. faecium BSI among cancer patients, especially
those treated previously with carbapenems. Clonal complex 17
was responsible for the large majority of E. faecium infections,
particularly in recent years. The emergence of E. faecium
among immunosuppressed cancer patients is worrying since
there are limited treatment options and it may presage the
emergence of vancomycin-resistant enterococci. Addressing
this trend for enterococci requires a rational approach that
combines infection control with antimicrobial stewardship.
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